What's Happening?
PharmaTher Holdings Ltd. has announced the establishment of PERSONALIZ3D, a new platform aimed at revolutionizing personalized medicine by integrating telehealth, pharmaceutical 3D printing, and pharmacy fulfillment. This initiative expands on their previous
Personaliz3D Peptides initiative, now including a broader range of therapeutic categories and compounded prescriptions. The platform is designed to produce personalized doses and combinations through digitally controlled pharmacy workflows, ensuring quality assurance and traceability. The global personalized medicine market is projected to grow significantly, from $570 billion in 2024 to $1.2 trillion by 2033, highlighting the potential impact of this development.
Why It's Important?
The launch of PERSONALIZ3D represents a significant shift in the healthcare industry towards more personalized treatment options. By leveraging 3D printing technology, PharmaTher aims to provide tailored therapies that meet individual patient needs, potentially improving treatment outcomes and patient safety. This approach could disrupt traditional telehealth and pharmacy models, offering a scalable alternative to fixed, off-the-shelf medications. The initiative also aligns with the growing demand for personalized medicine, which is expected to see substantial market growth in the coming years.
What's Next?
PharmaTher plans to advance PERSONALIZ3D through several stages, including establishing a Center of Excellence and launching a telehealth platform to connect patients with healthcare providers. The company will also evaluate and introduce pharmaceutical 3D-printing systems with pharmacy partners in the U.S. and Canada. As the platform develops, it could lead to broader commercial opportunities and partnerships, further expanding the reach and impact of personalized medicine.
